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Abstract: Aquatic organisms can be exposed to thousands of chemicals discharged by the human population. Many of these chemicals are
considered disruptive to aquatic wildlife, and the literature on the impacts of these chemicals grows daily. However, because time and
resources are not infinite, research must focus on the chemicals that represent the greatest threat. One group of chemicals of increasing
concern is pharmaceuticals, forwhich the primary challenge is to identifywhich represent the greatest threat. In the present study, a list of 12
pharmaceuticalswas compiled based on scoring the prevalence of different compounds fromprevious prioritization reviews. These included
rankingsbasedonprescriptiondata, environmental concentrations, predicted environmental concentration/predictedno-effect concentration
(PEC/PNEC) ratios, persistency/bioaccumulation/(eco)toxicity (PBT), and fish plasma model approaches. The most frequently cited were
diclofenac, paracetamol, ibuprofen, carbamazepine, naproxen, atenolol, ethinyl estradiol, aspirin, fluoxetine, propranolol, metoprolol, and
sulfamethoxazole. For each pharmaceutical, literature on effect concentrations was compiled and comparedwith river concentrations in the
United Kingdom. The pharmaceuticals were ranked by degree of difference between the median effect and median river concentrations.
Ethinyl estradiol was ranked as the highest concern, followed by fluoxetine, propranolol, and paracetamol. The relative risk of these
pharmaceuticals was compared with those of metals and some persistent organic pollutants. Pharmaceuticals appear to be less of a threat to
aquatic organisms than some metals (Cu, Al, Zn) and triclosan, using this ranking approach. Environ Toxicol Chem 2016;35:1021–1027.
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INTRODUCTION
Approximately 3000 pharmaceuticals are in general use
today in the European Union. Many of these pharmaceuticals
and/or their transformation products are found ubiquitously in
rivers in the developed world, at concentrations from sub-ng/L
to low µg/L [1]. Our scientific interest in pharmaceuticals and
the effect they have on the aquatic environment has increased
over the last 2 decades as our ability to detect them has
increased [2]. The scale of the threat that aquatic organisms face
with regard to the potential disruptive effect of these
biologically active chemicals is unknown. Pharmaceuticals
can enter surface waters via sewage effluent after use by
humans, via runoff from farmland after the application of
sewage sludge, directly from animals after veterinary pharma-
ceutical use, or directly following use in aquaculture. A possibly
underestimated source could be pharmaceutical manufacturing
sites, where concentrations in the local aquatic environment
have been found in the mg/L range [3]. Pharmaceuticals as a
class of chemicals have been designed to have biological
activity and resist inactivation sufficiently before delivering the
intended therapeutic effect. Therefore, we might expect their
discharge to the environment to have some inadvertent effects
on wildlife, particularly on vertebrates. The most notable
problems reported have been the severe effect of diclofenac on
vulture populations [4] and the disruptive effects of 17a-ethinyl
estradiol (EE2) on fish at very low concentrations [5,6]. Various
effects on fish, invertebrates, algae, and bacteria at varying
concentrations have also been reported for other pharmaceut-
icals [7,8]. But where does this risk sit in relation to the threat
posed by the other approximately 100 000 chemicals to which
aquatic organisms are potentially exposed in rivers?
The awareness of the potential harmful effects of pharma-
ceuticals is starting to be reflected in policy; 3 pharmaceuticals
are now on the European Union watch list—EE2, 17b-estradiol
(E2), and diclofenac—and are candidates for future control
under the Water Framework Directive of the European
Community [9]. Nevertheless, our knowledge on their effects
is still weak, especially with regard to chronic effect data.
Pharmaceuticals have been measured in the aquatic environ-
ment [1,10]; but even with the improvement in analytical
techniques to measure pharmaceuticals [3], very few measured
environmental data are available. There is still no routine
monitoring of pharmaceuticals to ascertain environmental
concentrations [1], and there is concern about using predicted
environmental data as an alternative [11]. It took more than
40 yr of research to gain a good knowledge of the discharges,
fate, and effects of 24 heavy metals. How will we cope with
doing the same job for 3000-plus pharmaceuticals? Where do
pharmaceuticals sit as chemicals of concern compared with
others, such as metals?
The present study describes an unbiased approach to
selecting 12 pharmaceuticals from the current literature to be
included in a wider study comparing the threat posed by
different classes of chemicals to aquatic organisms in the United
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Kingdom [12]. Environmental and ecotoxicological data
available in the literature for these 12 pharmaceuticals were
used to conduct a preliminary risk ranking. Fitting with
the wider study, the risks from these 12 pharmaceuticals were
compared with 2 other organics (triclosan and lindane) and 12
metals (Ag, Al, As, Cd, Cr, Cu, Fe, Hg, Mn, Ni, Pb, and Zn). In
terms of exposure of aquatic organisms to sewage effluent, the
United Kingdom could be considered to be among the most
exposed in Europe [13]; hence, if any chemical is harming
aquatic wildlife, then it is very likely that harmwill be occurring
in the United Kingdom.
METHODOLOGY
Pharmaceutical selection
For the present study, 12 pharmaceuticals were selected as
representatives of the class. Clearly, this is difficult, as many
different pharmaceuticals prioritization methods have been
suggested [14]. Each approach has its merits and weaknesses.
The aim was to identify the pharmaceuticals considered by the
scientific community as being of the greatest concern using a
simple metric approach. Thus, the top 12 ranked pharmaceut-
icals only reflect our current thinking. Scientists working in the
field have still examined only perhaps 100 out of 3000 different
pharmaceuticals. A concern highlighted in 2014 by Daughton
et al. [15] is the perception that perceived risk may be magnified
because of the popularity of a chemical to researchers. This is
represented by the number of papers and the data available per
pharmaceutical and can often be driven by external factors such
as fashion, media interest, and politics [15], something termed
the Matthew Effect. Using the Web of Knowledge, keywords
such as pharmaceuticals, ranking, prioritization, and reviews
were used to locate papers from the literature.
Different pharmaceutical prioritization approaches used by
environmental scientists
Sales and usage. The usage and sales data of pharmaceut-
icals can be obtained from annual prescriptions data, annual
sales, and annual usage data. This approach does not take into
account any ecological or toxicological data; it is based solely
on the amount of pharmaceutical used [14,16–19].
Occurrence in the environment. This approach is based on the
concentrations, either measured or predicted, of pharmaceuticals
in the environment. It takes into account only environmental
concentrations, not any ecotoxicology data [1,16,17,19].
Risk ratio. Typically, the risk ratio or quotient is calculated
from either predicted or measured water concentrations
and effect concentrations; the most common approach is
to determine the risk ratio using the predicted environmental
concentration/predicted no-effect concentration ratio (PEC/
PNEC). Other risk ratio variations exist, such as the use of
measured environmental concentrations [20] when these are
available. This approach does take into consideration
the toxicity of the chemical [14,17,21–23].
Multiple variables schemes. These approaches use multiple
variables to derive a risk assessment. These schemes include
persistency/bioaccumulation/(eco)toxicity (PBT), as well as
other methods that incorporate toxicity data, water concen-
trations, annual prescription data, solubility, and case-by-case
expert views [14,24–27].
Read-across theory
Fish plasma model. The fish plasma model calculates fish
plasma steady-state concentrations and compares thesewith human
therapeutic plasma concentrations for active pharmaceutical
ingredients [28]. Where an environmentally plausible water
concentration of a pharmaceutical is predicted to lead to a
plasma concentration in a fish close to the human therapeutic
concentration, that pharmaceutical is considered to be a high-
risk chemical [14,29,30].
Critical environment concentration. The critical environ-
mental concentration is the water concentration anticipated to
produce in fish a plasma concentration similar to the human
therapeutic concentration. Thus, the critical environmental
concentration is expected to cause physiological effects and is
obtained using literature data on human potencies together with
a predicted bioconcentration factor for fish based on lip-
ophilicity. It differs from the fish plasma model in that it is
independent of the exposure/PEC [14,31].
From the 22 pharmaceutical prioritization papers identified,
the lists of pharmaceuticals of potential concern were collated
into a database (see Table 1 for references used and
Supplemental Data, Table S1 for the complete database). The
frequency of pharmaceuticals appearing on these lists was used
to select the top 12. Thus, diclofenac, for example, ranked 1st,
with 18 citations from the 22 papers (Table 2). This approach
was chosen with the aim of providing as unbiased a selection of
12 pharmaceuticals as is currently possible. To state it another
way, if pharmaceuticals are causing a problem in the aquatic
environment, these are the pharmaceuticals that the scientific
community considers mostly likely to be involved.
Risk ranking
The first-tier ranking methodology used in the present
study has been described previously by Donnachie et al. [12];
a brief summary of the method is described in the following
sections.
Gathering environmental toxicity information: An uncritical
data collection process. A range of endpoints and effect
concentrations for each of the selected pharmaceuticals is found
in the literature, including lowest-observed-effect concentration,
median effect concentration, and median lethal concentration, as
well as acute toxicity and chronic toxicity concentrations. Awide
range of species and endpoints was considered to ensure a
representative spread of species and possible effects. The
endpoints included mortality, growth inhibition, and changes in
gene expression. In aquatic toxicological studies, bacteria,
daphnids, and fish were the most commonly used test species.
The data were collected from the literature during the summer of
2014 and may be seen as being representative of the research
available up to that time.
Measured water concentrations. If possible, measured
concentrations of pharmaceuticals in the United Kingdom
were used. These were obtained from the literature; because few
were found, however, the inclusion of predicted river values
helps to give a representative range of concentrations likely to
be encountered in UK rivers.
Predicted water concentrations. Predicted river concen-
trations start by using either reportedUK effluent concentrations
or consumption (UK)/excretion/sewage removal values before
considering river dilutions. Based on the work done by the
Centre for Ecology and Hydrology, the amount of dilution
available in the different regions of England and Wales is
known [32]. Also available was a range of dilution values for the
River Thames at Reading and the River Soar at Leicester [33],
which could be viewed as examples of likely river hot spots
(urbanized, with a high proportion of sewage effluent). By using
the dilution available from 90th percentile low-flow data for the
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Thames and Soar, this provides among the highest concen-
trations that fish might be exposed to in UK rivers. Reasonable
agreement between predictions and river measurements of
pharmaceutical concentrations has been demonstrated previ-
ously in the United Kingdom [32] and for Europe [34]. A benefit
of using predicted data if river water concentrations are
not available is that they can provide a wide range of
concentrations that reflect different geographies and flow
conditions. This provides a range of possible UK concen-
trations. At this stage, river attenuation was not included;
therefore, it could be said that the predicted values are likely
to represent a degree of overestimation and so represent a
precautionary approach. The measured and predicted water
concentrations have been combined and are referred to as water/
environmental concentrations.
Risk analysis
In the present study, each chemical was considered based on
water exposure, and hence the risk refers to that posed to aquatic
species through the water (not food). All endpoints and species
Table 1. Prioritization schemes used to generate the initial pharmaceuticals database
Scheme Summary Reference
Total references in
each group
Sales and usage
Amount used in the United Kingdom
(kg/yr)
[19] 5
Top 25 pharmaceuticals used in Denmark in
1997
(Drug Distribution Data [DDD])
[16]
Swedish sales statistics (kg/yr) [14,17]
Total amount consumed in Spain in 2003
(tonne/yr)
[18]
Occurrence in the environment
Occurrence in the environment globally
(Europe, North America, Asia)
[1] 4
European Union PECs [16]
PEC [17,19]
Risk ratio
Acute and chronic risk ratios [21] 5
PEC/PNEC [14]
MEC/PNEC [14]
Risk quotient [17]
EC5/MC95 [22]
Risk ratio [23]
Multiple variable schemes
PBT [14] 5
Pharmaceuticals in the Environment,
Information
for Assessing Risk (PEIAR) database
[14,24]
QSAR model [14]
Fish acute to chronic ratio [25]
Three-tiered scheme [26]
All species acute to chronic ratio [27]
Read-across theory
Fish plasma model [14,30] 3
Critical environment concentration [14,31]
Total 22
PEC¼ predicted environmental concentration; PNEC¼ predicted no-effect concentration; MEC¼measured environmental concentration; EC5¼ 5th
percentile effect concentration; MC95¼ 95th percentile measured concentration; PBT¼ persistency/bioaccumulation/(eco)toxicity; QSAR¼ quantitative
structure–activity relationship.
Table 2. Frequency of pharmaceuticals of concern cited in the 22 risk-prioritizing papers in the literature
Frequency citeda Pharmaceutical Type Use
18 Diclofenac (DCF) Nonsteroidal anti-inflammatory Relieving pain and reducing inflammation
17 Paracetamol (PAR) Analgesic (pain reliever) and antipyretic
(fever reducer)
Relieving headaches and other minor aches and pains
15 Ibuprofen (IBF) Nonsteroidal anti-inflammatory Relieving pain, alleviating fever, reducing inflammation
15 Carbamazepine (CBZ) Anticonvulsant and mood-stabilizing Treatment of seizure disorders and neuropathic pain (i.e., epilepsy)
15 Naproxen (NPX) Nonsteroidal anti-inflammatory Relieving pain, alleviating fever, reducing inflammation
11 Atenolol (ATN) Beta-blocker Cardiovascular diseases
11 Ethinyl estradiol (EE2) Estrogen Oral contraceptive pills
11 Aspirin (ASP) Analgesic (pain reliever) and antipyretic
(fever reducer)
Relief of headaches and other minor aches and pains
10 Fluoxetine (FLX) Antidepressant Depression
9 Propranolol (PRO) Beta-blocker Cardiovascular diseases
9 Metoprolol (MET) Beta-blocker Cardiovascular diseases
8 Sulfamethoxazole
(SMX)
Antibiotic Bacterial infections
aOut of the 22 prioritization articles examined in the literature.
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were included, with no other moderating factors considered at
this stage.
Ranking of chemicals based on exposure via the water. The
approach gathers 2 subsets of data, the effects data and the
environmental concentration data, with the proximity of these 2
datasets indicating the degree of concern posed by a chemical.
For the risk ranking, it was necessary to select a single
comparator to rank all of the chemicals. One possibility might
have been to compare the proximity of the lowest effect
concentration with the highest environmental concentration
(similar to PEC/PNEC). However, there is the possibility that
within both the effect and the environmental datasets there are
outliers that may be misrepresentative for a number of reasons.
These might include unrepeatable ecotoxicity results perhaps
with ambiguous endpoints or high environmental concentra-
tions from one-off localized polluted sites. Therefore, the
median value was considered the most robust comparator
between chemicals to indicate risk, as it is constructed from the
whole body of the 2 data sets (Equation 1) [12]. Themethod is in
effect trying to identify the chemical of greatest risk to the
widest group of water bodies in the United Kingdom.
Risk ¼ mW
mT
ð1Þ
In Equation 1,mW is themedian riverwater concentration (mg/L)
andmT is the median effect concentration (mg/L). This value can
be described as a risk ratio,which canbe used to rank concern; the
larger the value, the greater the concern.
Ranking of chemicals based on exposure via the water:
A precautionary approach. The precautionary approach uses
the 5th percentile ecotoxicity concentration (5%ileT; mg/L) and
compares it with the median river water concentration
(Equation 2). The 5th percentile ecotoxicity concentration
was calculated (using Excel) directly from the effect data
collected per chemical. Thus, this comparator gives greater
weight to the most sensitive endpoints such as might arise from
chronic ecotoxicity studies.
Risk ¼ mW
5%ileT
ð2Þ
Summary
The approach was devised to rank all chemicals discharged
by humans into the aquatic environment on the basis of
environmental risk. Although related to harm, it was not
designed to establish whether harm is in fact occurring. It was
considered essential to maintain consistency by using the same
method for data collection and analysis regardless of chemical.
There is an argument that this approach is not fit for
pharmaceuticals because chronic exposures causing nontoxic
endpoints are arguably more relevant than acute toxic effects.
Inclusion of acute effect data is likely to increase the median
values, thereby decreasing the apparent degree of risk. To give
greater weight to the chronic effects and sensitive endpoints,
therefore, all chemicals were also ranked by taking the lowest
5th percentile effects concentration to compare with the median
water concentration.
The method is limited by the quantity and quality of current
data in the literature on these pharmaceuticals. It should be
considered as an approach to reveal what we know now, and it is
accepted that this knowledge will grow with time and that
the rankings may alter in due course. It is intended that the
influence that moderating factors might have on the ranking will
be examined at a later stage. This might include a ranking
whereby the severity of the effect is given precedence; for
example, reproductive impacts might be ranked higher than
some other physiological effects.
Ranking of chemicals based on species group. Although the
overall objective of the present study was to compare chemicals
on the basis of risk to wildlife as a whole, it is instructive to tease
apart the wildlife data to review which species groups are more
vulnerable: fish, invertebrates, or algae. Comparison of different
groups of organisms can be based on the median effect
concentration and median water concentration as well as on
the 5th percentile effect concentration and median water
concentration.
RESULTS AND DISCUSSION
Selection of pharmaceuticals
This subgroup of pharmaceuticals was selected and ranked
based on different prioritization approaches found in the literature
(Table 1). Although this may not be an exhaustive review, our
objective was to provide a representative picture of some of
the pharmaceuticals of current concern with respect to the
environment. We are also aware that these are not the only
pharmaceuticals of potential concern and that our selection may
owe something to fashion and politics, rather than actual risk [15].
In the review of the pharmaceuticals prioritization literature,
it was found that diclofenac and paracetamol received the
highest citations. However, it was found that no 2 approaches
gave the same top 5 pharmaceuticals of concern when
comparing either different or similar approaches. It was for
this reason that the frequency of occurrence was used to make
the selection of the pharmaceuticals to investigate.
Risk ranking results
Ethinyl estradiol, fluoxetine, and propranolol were ranked of
highest concern when the medians were compared (Figure 1).
The pharmaceuticals for which the measured or predicted
concentrations actually overlapped with some reported effect
concentrations were EE2, fluoxetine, ibuprofen, carbamazepine,
and diclofenac (Figure 1). For all pharmaceuticals studied,
apart from EE2, the difference between the 2 median values
Figure 1. Comparison of literature effect concentrations (diamonds;
left-hand column of each pair) with measured (closed squares) and
predicted (open squares) UK river water concentrations (right-hand column
of each pair) for aspirin (ASP), atenolol (ATN), carbamazepine (CBZ),
diclofenac (DCF), ethinyl estradiol (EE2), fluoxetine (FLX), ibuprofen
(IBF), metoprolol (MET), naproxen (NPX), paracetamol (PAR), proprano-
lol (PRO), and sulfamethoxazole (SMX). The median values are plotted as
black circles, and the arrow depicts the reduction in risk ratio. The numbers
in parentheses represent the number of data points per data set.
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was greater than 100 000-fold, giving a risk ratio of 0.00001 or
less (Supplemental Data, Table S2). For EE2, the risk ratio was
0.0065, which was significantly higher than for the other
pharmaceuticals reported in the present study. When the ranking
was based on the difference between the 5th percentile effect
concentration and the median river water concentrations,
ibuprofen came 1st, with a risk ratio of 0.15, followed by EE2
(0.07), diclofenac (0.01), fluoxetine (0.01), and paracetamol
(0.01) (Supplemental Data, Figure S1). The ranking of
pharmaceuticals based on the 5th percentile effect data is a
more precautionary approach to ranking, as the focus is on the
most vulnerable species and the most sensitive endpoints. Even
when using the precautionary approach, the risk ratio of all the
pharmaceuticals was less than 1 (Supplemental Data, Table S2).
The reported effect concentration for EE2 ranged from
0.1 ng/L to 37.8 106 ng/L, with a median of 10 ng/L, whereas
the environmental concentrations ranged between 1.13 104
and 1.07 ng/L, with a median value of 0.065 ng/L. The lowest
reported effect concentration was 0.1 ng/L: a stimulatory effect
was seen with an increase in the mean number of eggs spawned
per pair in Pimephales promelas up to 1 ng/ L, but a decrease in
egg production was observed at 3 ng/L [35]. Fluoxetine was
ranked 2nd based on the comparison of median effect and river
concentrations. The range of effect concentrations for fluoxetine
was 0.0003mg/L to 111 357mg/L, with a median effect
concentration of 106mg/L. Antimicrobials may not have ranked
very high in this group of pharmaceuticals, but we should be
aware that there are other concerns with their use associated
with the possible development of antimicrobial resistance [36].
Sensitivity of different species to pharmaceuticals
Pharmaceuticals have often been designed to target specific
metabolic and molecular pathways common to vertebrates.
Species with similar targets may be more likely to experience
an effect as a result of the presence of pharmaceuticals in the
environment, because they have a comparable pathway [37].
The risk to each category of species was assessed based on
the risk ratio using the median effect value and the median river
water concentration (Figure 2). It would appear from the
selection of 12 that fish are the most sensitive species to
pharmaceuticals. Given that fish appear to contain many of the
same drug targets as humans, this is not surprising [29].
Considering the median data (Figure 2), EE2 is the pharmaceu-
tical of most concern to fish, with a risk ratio of 0.013. It is a
synthetic hormone that regulates reproductive functions in
vertebrates. In contrast to fish, EE2 is ranked 11th and 12th for
risk for algae and invertebrates, respectively, based on the
median data. Within each species group, it is likely that there
will be intraspecies sensitivity variation as well [7]. Paracetamol
was ranked as the highest risk for invertebrates and fluoxetine
the highest risk for algae, based on the median comparison.
However, these species are 100 times less sensitive to these
pharmaceuticals than fish are to EE2 (Figure 2).
Fluoxetine is one of the more studied pharmaceuticals. It has
been reported to be one of the most potentially disruptive human
drugs to aquatic species [38], and in the present study was ranked
1st, 3rd, and 4th for its risk to algae, invertebrates, and fish,
respectively. This suggested that fluoxetine is of concern to all
species groups, with algae being themore sensitive species group.
The median fluoxetine effect concentration for algae reported in
the present study was 45mg/L, with effects reported on the most
sensitive algae at 24mg/L, at which point fluoxetine effected the
growth of Pseudokirchneriella subcapitata [39]. The median
fluoxetine effect concentration for invertebrates identified in the
present study was 174mg/L, and the most sensitive species
appeared to be mussels, for which biochemical effects have been
reported at 0.0003mg/L [40]. Sumpter and Margiotta-Casaluci
2014 have openly questioned some of the reports claiming that
invertebrates are exquisitely sensitive tofluoxetine [41].When the
precautionary approach was taken (5th percentile effect concen-
tration vs median river concentration), ibuprofen was ranked
highest for both invertebrates andfish, andpropranololwas ranked
highest for algae (Supplemental Data, Figure S2).
Where do pharmaceuticals rank compared with other chemicals in
water risk?
To put the potential risk of pharmaceuticals into perspective
with other chemicals to which freshwater organisms are
exposed via the water, the calculated risk of pharmaceuticals
was comparedwith that of some other chemicals, using the same
approach. The first-tier risk ranking of metals and the organics
triclosan and lindane was reported in in 2014 in Donnachie
et al. [12]; this is an extension of that comparison. Triclosan is an
antimicrobial agent found in soaps, deodorants, skin creams,
and plastics and has been used in homes since the 1960s.
Lindane (g- hexachlorocyclohexane) is a pesticide designed to
act as a neurotoxin and has been banned from agricultural use
around the world since 2009. From this comparison, several
metals (Cu, Al, and Zn) are indicated as being of greater concern
than the highest ranked pharmaceutical (EE2); triclosan and
lindane are ranked 5th and 12th, respectively (Figure 3). This
ranking is based on exposure via the water; accumulation of
chemicals by the biota was not considered (whereby mercury
would assume much higher importance).
CONCLUSIONS
We have limited resources to protect the aquatic environ-
ment. We should therefore focus these resources on the greatest
threats, which may not even be chemicals [42]. Nevertheless,
chemicals discharged from human activities are a threat that we
are struggling to assess. From this preliminary assessment,
pharmaceuticals do not appear to pose as great a risk to aquatic
wildlife as do many metals and triclosan. With this approach,
Figure 2. Ranking of pharmaceuticals—aspirin (ASP), atenolol (ATN),
carbamazepine (CBZ), diclofenac (DCF), ethinyl estradiol (EE2), fluoxetine
(FLX), ibuprofen (IBF), metoprolol (MET), naproxen (NPX), paracetamol
(PAR), propranolol (PRO), and sulfamethoxazole (SMX)—by all species
(A), fish (B), invertebrates (C), and algae (D). Rankings are based on a risk
ratio comparing the median effect concentration and median river water
concentration.
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there may be concerns about the nature and relevance of
ecotoxicity effects unduly influencing the ranking one way or
another, but there could also be potential issues with measure-
ments that may be unduly dominated by high exposure/spill
sites. No ranking system will ever be perfect. This review has
considered only 12 out of a possible 3000-plus pharmaceuticals
and hence represents an initial look at the impacts of an
expanding class of chemical contaminants. What has been
highlighted is that only a very small proportion of pharmaceut-
icals has been studied sufficiently (and to a reliable standard) to
make even preliminary judgments on whether they pose a risk.
The limitations of time and funding reinforce the need for
intelligent approaches and predictive tools to gauge the
environmental concentrations and the effects of pharmaceut-
icals on aquatic organisms. It is not going to be possible to
measure, monitor, or conduct robust long-term studies of the
effects of all pharmaceuticals, or probably even 10% of them, on
aquatic organisms [43]. The prominence of EE2 in any risk
ranking may be an indication that we should focus our efforts on
hormonally acting pharmaceuticals [44].
Importantly, the occurrence of high concentrations of
pharmaceuticals at specific sites [3] and the reports of effects
occurring in the low ng/L range of some pharmaceuticals [45]
suggest that possible effects as a result of the presence of
pharmaceuticals in the environment do occur, notwithstanding
their low ranking here. Classing pharmaceuticals as “not a
problem” would be premature; but in comparison with other
chemicals and based on the current state of the science, this
preliminary risk assessment ranks them as less of a threat.
Supplemental Data—The Supplemental Data are available on the Wiley
Online Library at DOI: 10.1002/etc.3165.
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